Essaouira Fishing Port – March 29, 2021 – Essaouira, Morocco
By Tom Allin
First thing I did this morning after making my morning check to confirm I was still breathing was to go to the parking lot to retrieve an item or two we had forgotten to unload yesterday. On the way back I stopped In Essaouira’s Moulay Hassan Square for a cup of coffee.
The square is huge and as you can see: empty. Essaouira has morphed from a fishing port into a tourist center during the last twenty years. However, being a year into the pandemic and Morocco still limiting Europeans and others in visiting plus the mandated closing of all restaurants at 8:00 pm has brought tourism to a standstill.
Nancy and I spent 30 minutes or more looking for the perfect café for an American egg and black coffee breakfast. When our search turned up nothing we sat down at a café, ordered eggs and coffee, and sat back to enjoy the morning.
If I didn’t have Medicare Part D, my out-of-pocket monthly expense would be about $960; Eliquis alone, without Medicare, would be $450 a month. My personal cost is about $80 a month with almost 40 percent of that amount for Eliquis alone.
Big Pharma gets away with their pricing because members of Congress are bought and paid for via campaign contributions.
Ask yourself: Why are identical drugs exponentially cheaper in other counties?
Why is a drug that costs $10 a day in Canada cost 10 times that amount in the U.S.? On average, Canadian patients pay 40 percent less than Americans.
The U.S. allows market competition to control medication pricing. This has led to higher medication prices in the U.S. than in other countries. The government in many other countries directly or indirectly manages drug costs.
The U.S. competitive marketing system, allows pharmaceutical companies to make significant profits. Manufacturers counter this complaint stating a need for profits to incentivize high-risk research.
In order for a manufacturer to get a product to market, they must pass many layers of government approval.
Between 2011 and 2015, Medicare recipients saw a 62 percent increase for brand-name drugs. The salary and pension income for those over the age of 65, however, did not meet this 62 percent rise. Thus, the steep rise in medication prices makes it very difficult for people to keep up.
Are medications really cheaper in Canada?
PharmacyChecker reports that many brand-name prescription medicines are less expensive in Canada. Yet, the U.S. Generic medications are often cheaper in the U.S. than in Canada.
Research on 20 popular brand-name drugs found a possible average savings of 70 percent when purchased in Canada. Some examples of 90-day supplies in October 2018 include:
Premarin 0.625 mg costs $623.70 in U.S. vs. $76.61 in Canada
Januvia 100 mg costs $1,593.90 in the U.S. vs. $269.94 in Canada
Crestor 10 mg costs $969.30 in the U.S. vs. $204.02 in Canada
Advair Diskus 250/50 mcg costs $1,437.99 in the U.S. vs $383.74 in Canada
Nexium 40 mg costs $863.10 in the U.S. vs. $149.94 in Canada
The U.S. government could create laws to set lower prices. Here, however, money talks and Big Pharma’s lobby
lobbyists talk BIG and LOUD!
Nothing will change until we — you, me, us, them — scream BIG and just as LOUDLY!
GIVE US YOUR FEEDBACK. CLICK ON “COMMENT” TO TELL US WHAT YOU THINK or use one of the alternative methods for providing feedback.
PFIZER VACCINE AVAILABLE TODAY AND TOMORROW AT ETBU:
FROM NYT COVID TRACKER:
1. Higher Stroke Risk Linked to Asymptomatic COVID-19 in Younger Men(CIDRAP) Men under 50 recovering from asymptomatic COVID have double the likelihood of acute ischemic strokes (AIS) compared with men of the same age without COVID infection, according to a study last week in JAMA Network Open. Eighteen South Asian men were treated in Singapore for AIS a median of 54.5 days after their initial COVID-19 diagnosis. Twelve (67.7%) had no known pre-existing risk factors. While AIS is a known neurologic complication from symptomatic COVID-19, none of these men experienced respiratory symptoms during their infection.
2. U.S. to Share AstraZeneca Covid-19 Vaccine Doses With World (WSJ)
The Biden administration is making plans to share millions of doses of the AstraZeneca Covid-19 vaccine and preparing a major effort to help India fight a resurgence of the virus, as calls mount for the U.S. to do more to assist developing countries in confronting the pandemic. The White House said Monday it would share as many as 60 million doses of the AstraZeneca vaccine with the rest of the world. U.S. officials also said they were exploring options to urgently dispatch oxygen and related supplies to India.
3. Brazil Rejects Russia’s Sputnik V Coronavirus Vaccine, Citing Safety Concerns (The Washington Post) Brazilian health regulators have issued a scathing rebuke of Russia’s Sputnik V coronavirus vaccine, rejecting the shot’s approval in a decision late Monday that could impact its use elsewhere in the world. The ruling from Brazil’s Health Regulatory Agency, or Anvisa, cited a range of concerns with the vaccine’s development and production, including what it said was a lack of quality control and efficacy data, as well as little if any information on the shot’s adverse effects. It was not the first time that health authorities have raised concerns about Sputnik V, which was hailed as “safe” and more than 91 percent effective in a peer-reviewed article in the Lancet in February.
FROM HOPKINS AND CDC A REAL NURSING HOME STORY WITH PROOF VACINES WORK:
NURSING HOME OUTBREAKSHealth officials in Kentucky and experts at the US CDC published a case study of an outbreak at a long-term care facility (LTCF) initiated by an unvaccinated employee. At the facility, 90% of the residents and 53% of the staff received 2 doses of SARS-CoV-2 vaccine. Routine testing identified the outbreak, which began in an unvaccinated and symptomatic healthcare worker. Ultimately, the outbreak involved 46 total cases, including 26 residents and 20 facility personnel. Notably, 18 of the residents and 4 personnel received their second dose of the vaccine more than 14 days before the outbreak. Three (3) residents died, including 2 who were unvaccinated.
The risk of infection among unvaccinated residents was 3 times higher than among vaccinated residents. Similarly, the risk among unvaccinated personnel was 4 times higher than among vaccinated personnel. For this outbreak, the vaccine’s effectiveness against SARS-CoV-2 infection was estimated to be 66% among residents and 76% among employees, and the effectiveness against symptomatic COVID-19 disease was 86.5% among residents and 87% among employees. This is in line with the expected effectiveness based on clinical trial efficacy data. The authors conclude that low vaccination coverage among employees at LTCFs could facilitate introduction of SARS-CoV-2, which could result in outbreaks, even among resident populations with high vaccination coverage. While the authorized SARS-CoV-2 vaccines are highly effective*, COVID-19 risk remains, particularly among individuals at elevated risk for exposure and severe disease. Even as vaccination coverage increases, it is critical to maintain COVID-19 risk mitigation measures until sufficient community protection is in place to bring the pandemic under control.
*For those vaccines with publicly available Phase 3 clinical trial data.
(J. Harris: I’m not interested in discussing politics, but Marshall hospitals treat many uninsured patients as well as a large number of Medicaid-funded patients — whose payments are inadequate and not capable of paying a significant amount of the expenses incurred. Marshall is too close to hospitals in Longview and Shreveport to be considered “Rural,” a designation that would help us financially. Around ten years ago, a good local hospital administrator told me that Texas’ approach to Medicaid would bankrupt our hospital as well as many other smaller Texas hospitals. He was correct in his prediction. Many smaller hospitals have closed. In my opinion, only partially informed, had Christus not bought the Good Shepherd hospitals in Longview and Marshall, I’m not sure that either would still be functional. What do you think? What do you think about increasing Texas’ participation in Medicaid?
The article below is written by Tom Luce who I know and trust: